98%
921
2 minutes
20
Background: Pancreatic cancer is one of the most malignant tumors of the digestive system, and its treatment has rarely progressed for the last two decades. Studies on m6A regulators for the past few years have seemingly provided a novel approach for malignant tumor therapy. m6A-related factors may be potential biomarkers and therapeutic targets. This research is focused on the gene characteristics and clinical values of m6A regulators in predicting prognosis in pancreatic cancer.
Methods: In our study, we obtained gene expression profiles with copy number variation (CNV) data and clinical characteristic data of 186 patients with pancreatic cancer from The Cancer Genome Atlas (TCGA) portal. Then, we determined the alteration of m6a regulators and their correlation with clinicopathological features using the log-rank tests, Cox regression model, and chi-square test. Additionally, we validated the prognostic value of m6A regulators in the International Cancer Genome Consortium (ICGC).
Results: The results suggested that pancreatic cancer patients with CNV were associated with worse overall survival and disease-free survival than those with diploid genes. Additionally, upregulation of the writer gene had a positive correlation with the activation of AKT pathways in the TCGA database.
Conclusion: Our study not only demonstrated genetic characteristic changes of m6A-related genes in pancreatic cancer and found a strong relationship between the changes of and poor prognosis but also provided a novel therapeutic target for pancreatic cancer therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147537 | PMC |
http://dx.doi.org/10.1155/2021/5573628 | DOI Listing |
Chembiochem
September 2025
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, P. R. China.
The ATPase caseinolytic protease X (ClpX), forming the ClpXP complex with caseinolytic protease P (ClpP), is essential for mitochondrial protein homeostasis. While ClpP targeting is a recognized anticancer strategy, the role of ClpX in cancer remains underexplored. In pancreatic ductal adenocarcinoma (PDAC), elevated CLPX expression correlates with poor prognosis, suggesting its oncogenic function.
View Article and Find Full Text PDFAnn Palliat Med
September 2025
Brown University Health Cancer Institute, Providence, RI, USA; Division of Geriatrics and Palliative Medicine, Department of Medicine, Alpert Medical School of Brown University, Providence, RI, US.
ancreatic cancer is an aggressive disease and often presents at an advanced stage with no curative options. The disease is often characterized by rapid progression, limited or short-lived responsiveness to standard therapies, and a profound impact on patients' quality of life. Despite advances in targeted therapies and immunotherapy, curative outcomes remain elusive for the majority of patients with advanced or high-grade disease with a 5-year survival rate of less than 10%.
View Article and Find Full Text PDFChemistry
September 2025
Department of Chemistry, Birla Institute of Technology and Science-Pilani, K K Birla Goa Campus, Zuarinagar, Goa, 403726, India.
This study investigates the unique syneresis (self-shrinking) behavior of N-Terminally Fmoc-protected amino acid, Fmoc-hPhe-OH (Fmoc-homo-L-phenylalanine, abbreviated in this work as hF)-based hydrogel, and its potential in environmental remediation applications. Fmoc-hPhe-OH (hF) forms a hydrogel in 50 mM phosphate buffer (PB) of pH 7.4.
View Article and Find Full Text PDFMol Ther
September 2025
Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China; State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Pancreatic Cancer Heterogeneity, Candiolo Cancer Institute
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis, partly due to cancer stem cells (CSCs) that drive progression and treatment resistance. We explored the therapeutic potential of inducing cuproptosis, a copper-dependent regulated cell death, in CSC-enriched PDAC models. Using human and murine PDAC models, we evaluated elesclomol, a copper transport enhancer.
View Article and Find Full Text PDFSurg Endosc
September 2025
Department of Next Generation Endoscopic Intervention (Project ENGINE), Graduate School of Medicine, The University of Osaka, Suite 0802, BioSystems Bldg., 1-3, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Objective: Rigid suction-coagulation probes constrain the wrist-like articulation that is central to robotic surgery. We therefore designed a 5-mm single-use flexible suction ball coagulator (flex-SBC) with a modified core design to restore dexterity and assessed its mechanical performance and early clinical feasibility, including the effect of the common robotic gripping strategies on suction flow.
Methods: Preclinical.